SER (2019) [32] |
FRAX BMD (if FRAX 10-year risk of major osteoporotic fracture ≥5%) |
Postmenopausal women and men aged ≥50 years with GC ≥5 mg/day BMD T-score ≤−1.5 OR FRAX 10-year risk of hip fracture ≥3% OR FRAX 10-year risk of major osteoporotic fracture ≥10% without BMD OR FRAX 10-year risk of major osteoporotic fracture ≥7.5% with BMD Premenopausal women and men aged <50 years with GC ≥7.5 mg/day BMD Z-score ≤−3 |
All adults Prior fragility fracture OR Initial GC ≥30 mg/day |
|
KSBMR/KCR (2018) [30] |
Adults aged ≥40 years FRAX (GC-adjusted)a BMD (within 6 months of GC initiation) |
Adults aged ≥40 years BMD T-score ≤−2.5 (postmenopausal women and men aged ≥50 years) OR FRAX 10-year risk of major osteoporotic fracture ≥10% OR FRAX 10-year risk of hip fracture >1% |
All adults Prior fragility fracture OR Very high dose GCsc (age ≥30 years) |
|
Adults aged <40 years BMD at high risk (within 6 months of GC initiation) |
Adults aged <40 years with GC ≥7.5 mg/day BMD Z-score <−3 OR ≥10%/year loss of BMD |
|
|
ACR (2017) [33] |
Adults aged ≥40 years FRAX (GC-adjusted)a BMD (if available) (within 6 months of GC initiation) |
Adults aged ≥40 years BMD T-score ≤−2.5 (postmenopausal women and men aged ≥50 years) OR FRAX 10-year risk of major osteoporotic fracture ≥10% OR FRAX 10-year risk of hip fracture >1% |
All adults Prior fragility fracture OR Very high dose GCsc (age ≥30 years) |
|
Adults aged <40 years BMD at high risk (within 6 months of GC initiation) |
Adults aged <40 years with GC ≥7.5 mg/day BMD Z-score <−3 OR ≥10%/year loss of BMD |
|
|
NOGG (2017) [31] |
FRAX (GC-adjusted)b BMD at intermediate risk |
Postmenopausal women and men aged ≥50 years Age ≥70 years OR GC ≥7.5 mg/day OR FRAX above intervention threshold |
All adults Prior fragility fracture |
|
|
Premenopausal women and men aged <50 years High dose GCs |
|
|
SIOMMMS (2016) [41] |
DeFRA (GC-adjusted) |
Postmenopausal women and men aged ≥50 years GC ≥5 mg/day for ≥3 months |
|
|
SEIOMM (2015) [40] |
NA |
Postmenopausal women and men aged ≥50 years GC dose ≥5 mg/day for ≥3 months |
|
|
|
Premenopausal women and men aged <50 years Prior fragility fracture OR very low BMD OR very high dose GCs |
|
|
SFR/GRIO (2014) [39] |
BMD (GC use ≥3 months) VFA (GC ≥7.5 mg/day for ≥3 months) |
Postmenopausal women and men aged ≥50 years Prior fragility fracture OR age ≥70 years OR GC ≥7.5 mg/day for ≥3 months OR BMD T-score ≤−2.5 OR FRAX (GC-adjusted)b above intervention threshold (when not applicable of above indications) |
|
|
|
Premenopausal women and men aged <50 years GC use ≥3 months plus fragility fracture |
|
|
JSBMR (2014) [42] |
Score based on prior fragility fracture, age, GC dose, and lumbar spine BMD (% YAM) |
Calculated individual patient’s score ≥3 |
|
|
IOF-ECTS (2012) [37] |
FRAX (GC-adjusted)b BMD (if available) at intermediate risk |
Postmenopausal women and men aged ≥50 years Prior fragility fracture OR age ≥70 years OR GC ≥7.5 mg/day for ≥3 months OR BMD T-score ≤−1.5 OR FRAX above intervention threshold |
|
|
|
Premenopausal women and men aged <50 years GC use ≥3 months plus fragility fracture |
|
|
SBR/BMA/ABMFR (2012) [38] |
BMD |
Postmenopausal women GC ≥5 mg/day for ≥3 months |
|
|
|
Men Planning to initiate GC ≥5 mg/day for ≥3 months plus T score ≤−1.0 Already using GC ≥5 mg/day for ≥3 months plus T score ≤−1.8 |
|
|
Osteoporosis Canada (2010) [35] |
BMD (GC ≥7.5 mg/day for ≥3 months) |
Adults aged >50 years GC ≥7.5 mg/day for ≥3 months |
|
|
DVO (2009) [36] |
Women aged ≥50 years and men aged ≥60 years BMD (if GC use ≥3 months) |
GC ≥7.5 mg/day for ≥3 months and BMD T-score ≤−1.5 |
|
|
Women aged <50 years and men aged <60 years BMD (if GC ≥7.5 mg/day for ≥3 months) |
|
|
|
BBC (2006) [34] |
NA |
GC ≥7.5 mg/day for ≥3 months |
|